GSK seeks European nod for promising Hepatitis B therapy

Biogen unveils promising new data for Salanersen in kids with SMA

Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains

Lonza scales bioconjugate innovation through enhanced synthesis offering

Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization

Scinai acquires Recipharm Israel to expand global reach

This transaction fundamentally strengthens Scinai's CDMO platform

Codexis teams up with Axolabs to advance enzymatic RNA manufacturing

The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology

GSK reports breakthrough results in chronic hepatitis B trials

US House passes Bill reauthorizing FDA rare disease incentive program

Novartis to acquire Avidity Biosciences for $12 billion

The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company

Lundbeck and Contera Pharma join forces to advance RNA therapies for neurological disorders

Contera Pharma will receive an upfront payment and full research funding for each target under investigation

Cohance Lifesciences reports 13% revenue growth in Q1 FY26

During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site